| Pair Name | Tanshinone IIA, Sorafenib | ||
| Phytochemical Name | Tanshinone IIA (PubChem CID: 164676 ) | ||
| Anticancer drug Name | Sorafenib (PubChem CID: 216239 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Tanshinone IIA, Sorafenib | |||
| Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
| Biological Phenomena | Inhibition-->Epithelial-mesenchymal transition | |||
| Gene Regulation | Down-regulation | Phosphorylation | STAT3 | hsa6774 |
| In Vitro Model | Huh-7 | Adult hepatocellular carcinoma | Homo sapiens (Human) | CVCL_0336 |
| Hep-G2 | Hepatoblastoma | Homo sapiens (Human) | CVCL_0027 | |
| MCF-7 | Invasive breast carcinoma of no special type | Homo sapiens (Human) | CVCL_0031 | |
| Result | A combination therapy using Tan-IIA and sorafenib or SC-1 could be a promising approach to target HCC, and further preclinical investigations are warranted to establish their synergetic advantage. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Synergistic antitumor effects of tanshinone IIA and sorafenib or its derivative SC-1 in hepatocellular carcinoma cells. Onco Targets Ther. 2018 Mar 29;11:1777-1785. doi: 10.2147/OTT.S161534. | Click |
